- Reaney M et al. Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ):a new patient-reported outcome (PRO) instrument. Pharmacoecon Open. 2022;6:563-574.
- Reaney M et al. Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial. Pharmacoecon Open. 2022;6:575-586.
- Zaiser E et al. Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life. J Patient Rep Outcomes. 2020;4:102-112.
- Kosinski M et al. Patient-reported outcome measure development and validation: a primer for clinicians. J Allergy Clin Immunol Pract. 2024;12:2554-2561.
- Zannad F et al. Patient-reported outcome measures and patient engagement in heart failure clinical trials: multi-stakeholder perspectives. Eur J Heart Fail. 2023;25:478-487.
- Price J et al. Validation of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) 7-day recall. Poster presentation at the ACC 2025 meeting; March 29-31, 2025; Chicago, Illinois. Abstract 11377.
Hypertrophic cardiomyopathy (HCM) is a chronic, progressive myocardial disorder characterized by left ventricular hypertrophy.1 HCM is classified as obstructive or nonobstructive based on the presence or absence, respectively, of left ventricular outflow tract obstruction.2 Based on patients’ experiences with obstructive and nonobstructive HCM, core symptoms include dyspnea, fatigue, chest pain, dizziness, palpitations, and syncope.1,3 These symptoms can have physical, emotional, and social impacts on patients and may contribute to significant impairment in quality of life.2,3
Treatment goals in HCM focus on the relief of symptoms.1 As such, incorporating patient perspectives into drug development and clinical practice is important.3-5 The Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) is the first HCM-specific patient-reported outcome (PRO) measure designed to assess patient symptoms.1 The HCMSQ was developed rigorously and iteratively in line with FDA guidance on PRO development.1 It was also based on a previously published HCM disease conceptual model that incorporated evidence from a literature review, a patient online survey, clinician interviews, and in-depth patient interviews.1-3
This 9-item HCMSQ produces 4 domain scores (shortness of breath [4 items], tiredness [1 item], cardiovascular symptoms [3 items], and syncope [1 item]), of which the first 3 domains are combined to create a total score, with lower scores indicating a lower presence of symptoms overall.1,2 It is a short questionnaire and typically takes less than 2 minutes to complete.
The HCMSQ has 2 versions: the 24-hour recall version (HCMSQ-24h) and the 7-day recall version (HCMSQ-7d).1,2,6
The HCMSQ-24h has been translated into multiple languages and is used to derive key
study endpoints in clinical trials in HCM. It has been validated in obstructive HCM.2 The HCMSQ-24h
is completed daily by participants, with scores aggregated over a week’s time to provide a weekly
average symptom score.1,2
The HCMSQ-7d was developed to facilitate the use of the
HCMSQ in clinical trials and support its utility in routine cardiovascular clinical practice (eg,
completion once per week vs 7 times per week). It has been qualitatively validated in adults with
HCM.6 Other efforts to validate the 7-day recall version are still ongoing. The HCMSQ-7d has been
translated into multiple languages and has been used to derive key study endpoints in several HCM
studies.
Download the HCMSQ
There are 2 versions of the HCMSQ: 24-hour recall and 7-day recall. Please select a language from the drop-down menus under each version to download the specific HCMSQ form. Manuals can also be downloaded.
Please email HCMSQ@bms.com if you would like to license a language not listed here.
CV-US-2500062 03/25
